Etoposide-Hexal 50mg / 2.5ml. 100mg / 5ml. 200mg / 10ml. 400mg / 20ml. 1000mg / 50ml Infusion
PDF Leaflet Revision Date: 29 June 2019
Clinical Summary
Quick overview from the medicine insert
Indication
Management of testicular and small cell lung tumors.
Dosage (summary)
IV: 50-100 mg/mu00b2/day for 5 days or 100 mg/mu00b2 on days 1, 3, 5 every 3-4 weeks.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Can cause fetal harm; effective contraception required during treatment.
Key Drug Interactions
- Ciclosporin
- Cisplatin
- Phenytoin
- Warfarin
Contraindications
- Hypersensitivity to etoposide
- Severe hepatic dysfunction
- Bone marrow depression
- Renal impairment
Common side effects
- Myelosuppression
- Leukopenia
- Thrombocytopenia
- Anaphylactic reactions
- Nausea
Counselling Points
- Monitor for signs of infection
- Avoid live vaccines
- Report any bleeding or bruising
Serious warnings
- Severe myelosuppression
- Risk of anaphylaxis
- Tumor lysis syndrome
Important Disclaimer
The Etoposide-Hexal 50mg / 2.5ml. 100mg / 5ml. 200mg / 10ml. 400mg / 20ml. 1000mg / 50ml Infusion professional information leaflet below is the property of Sandoz and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
